BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31047858)

  • 21. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
    Nie S; Zhang L; Liu J; Wan Y; Jiang Y; Yang J; Sun R; Ma X; Sun G; Meng H; Xu M; Cheng W
    J Exp Clin Cancer Res; 2021 Sep; 40(1):284. PubMed ID: 34496932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutually exclusive antiproliferative effect of cell line-specific HOX inhibition in epithelial ovarian cancer cell lines: SKOV-3 vs RMUG-S.
    Kim M; Suh DH; Choi JY; Lee S; Bae JR; Kim K; No JH; Kim YB
    J Cell Mol Med; 2020 Mar; 24(5):3246-3251. PubMed ID: 31970886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
    Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
    Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer.
    Gambelli A; Nespolo A; Rampioni Vinciguerra GL; Pivetta E; Pellarin I; Nicoloso MS; Scapin C; Stefanatti L; Segatto I; Favero A; D'Andrea S; Mucignat MT; Bartoletti M; Lucia E; Schiappacassi M; Spessotto P; Canzonieri V; Giorda G; Puglisi F; Vecchione A; Belletti B; Sonego M; Baldassarre G
    EMBO Mol Med; 2024 May; 16(5):1162-1192. PubMed ID: 38658801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Over-expression of nuclear NF-κB1 and c-Rel correlates with chemoresistance and prognosis of serous epithelial ovarian cancer.
    Shuang T; Wang M; Zhou Y; Shi C
    Exp Mol Pathol; 2016 Feb; 100(1):139-44. PubMed ID: 26683819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
    Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
    J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.
    Cao P; Zhao S; Sun Z; Jiang N; Shang Y; Wang Y; Gu J; Li S
    Exp Cell Res; 2018 Oct; 371(1):214-221. PubMed ID: 30118697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance.
    Wang T; Fahrmann JF; Lee H; Li YJ; Tripathi SC; Yue C; Zhang C; Lifshitz V; Song J; Yuan Y; Somlo G; Jandial R; Ann D; Hanash S; Jove R; Yu H
    Cell Metab; 2018 Jan; 27(1):136-150.e5. PubMed ID: 29249690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical interaction of STAT1 isoforms with TGF-β receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer.
    Tian X; Guan W; Zhang L; Sun W; Zhou D; Lin Q; Ren W; Nadeem L; Xu G
    J Exp Clin Cancer Res; 2018 May; 37(1):103. PubMed ID: 29751820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.
    Sonego M; Poletto E; Pivetta E; Nicoloso MS; Pellicani R; Vinciguerra GLR; Citron F; Sorio R; Mongiat M; Baldassarre G
    Cells; 2019 Dec; 9(1):. PubMed ID: 31861382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NANOG Metabolically Reprograms Tumor-Initiating Stem-like Cells through Tumorigenic Changes in Oxidative Phosphorylation and Fatty Acid Metabolism.
    Chen CL; Uthaya Kumar DB; Punj V; Xu J; Sher L; Tahara SM; Hess S; Machida K
    Cell Metab; 2016 Jan; 23(1):206-19. PubMed ID: 26724859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming.
    Feng Y; Tang Y; Mao Y; Liu Y; Yao D; Yang L; Garson K; Vanderhyden BC; Wang Q
    Int J Oncol; 2020 Mar; 56(3):697-708. PubMed ID: 31922217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
    Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
    Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
    Cao L; Wan Q; Li F; Tang CE
    BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers.
    Wang Y; Lu JH; Wang F; Wang YN; He MM; Wu QN; Lu YX; Yu HE; Chen ZH; Zhao Q; Liu J; Chen YX; Wang DS; Sheng H; Liu ZX; Zeng ZL; Xu RH; Ju HQ
    Cancer Lett; 2020 Mar; 473():74-89. PubMed ID: 31904482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.